A Phase I/II clinical trial found that nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of PD-L1 marker presence. The treatment was well-tolerated and showed a median survival of at least one year for 45.6% of patients.
A Phase 3 clinical trial found that patients with high-risk neuroblastoma who received two autologous stem-cell transplants had higher event-free and overall survival rates compared to those who underwent a single transplant. The study also showed improved outcomes when immunotherapy was added to the treatment regimen.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in the treatment of endometrial and ovarian cancers. A Phase II trial combining everolimus, letrozole, and metformin shows a 67 percent clinical benefit rate for patients with recurrent endometrioid endometrial cancer. Additionally, hormonal maintenance therap...
A phase II clinical trial found that pembrolizumab reduces tumor size in four types of soft tissue sarcomas and three types of bone sarcomas. Undifferentiated pleomorphic and osteosarcoma subtypes showed particularly promising results, with 44% and 30-40% reductions in tumor size, respectively.
A clinical trial found that patients with tumors overexpressing DLL3 responded better to the experimental drug rovalpituzumab tesirine (Rova-T), achieving stabilization of disease and significant tumor reductions. The results suggest Rova-T may be a promising treatment option for advanced small cell lung cancer.
Researchers from Tomsk State University have discovered that bats can act as transmitters of infections, including those caused by bacteria and nematodes. The study found gamasid mites in bat samples, which are common among rodents, indicating close contact between the two species.
LA BioMed researchers find a new study on aromatase inhibitors to prevent breast cancer recurrence is reassuring. The study's findings have direct application for clinical practice, with implications for cardiologists and oncologists.
A clinical trial shows atezolizumab, a checkpoint inhibitor, is effective in treating advanced bladder cancer, shrinking tumors and stopping new growth. The drug was well-tolerated, with mild side effects, and half of patients responded within 15 weeks.
A global review of systematic reviews found that people under 35, particularly women, are disproportionately affected by anxiety disorders. The study also highlighted the importance of understanding how common these disorders are and which groups are at greatest risk, especially those with chronic health conditions.
A Phase II clinical trial conducted by MD Anderson Cancer Center found that nivolumab significantly improves outcomes for patients with squamous cell carcinoma of the anal canal, with a control rate of 70%. The study enrolled 39 patients and demonstrated efficacy in both HIV-positive and non-HIV positive populations.